AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Amgen

Bristol-Myers

Cerevel Therapeutics Holdings Inc

Horizon Pharma

ImmunoGen

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca's early Vaccines & Immune Therapies pipeline. Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose's proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bact.

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

LONDON & BUDAPEST, Hungary--(BUSINESS WIRE)--Turbine, a leading biological simulation company building a platform for interpreting human biology in silico, today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers. The collaboration will focus on understanding resistance mechanisms.

Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers

Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.

Why the Market Dipped But Astrazeneca (AZN) Gained Today

Chevron

Amdocs

Barrick Gold

Lockheed Martin

Scorpio Tankers

Vale S.A.

I believe that 2024 will be good for equities. Potential rate cuts are a big impending catalyst.

7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024

GlaxoSmithKline

GSK PLC (LSE:GSK, NYSE:GSK) shares got a shot in the arm this morning after Jefferies took a more positive view of the pharmaceuticals giant. The US investment bank upgraded its rating to ‘buy' from ‘hold' and increased its price target to 1,900p from 1,550p.

GSK gets shot in arm from upgrade, AstraZeneca mixed reviews after China deal

C4X Discovery Holdings PLC (AIM:C4XD) has reached what has been described as a "significant milestone" after receiving an $11 million payment under its $402 million deal with pharma giant AstraZeneca PLC (LSE:AZN). Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ.

C4X Discovery receives $11m AstraZeneca milestone payment

NATICK, Mass. , Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

Sanofi

AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.

AstraZeneca, Sanofi's RSV infant shots approved in China

Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca PLC (LSE:AZN) is set to acquire Gracell Biotechnologies, the Chinese company specialising in innovative cancer and autoimmune disease treatments, for US$1.2 billion The US$2 per share acquisition provides AstraZeneca access to platforms potentially shortening manufacturing times and enhancing the development of more efficient cell therapy treatments. Gracell's T-cell therapy, GC012F, is particularly promising for blood cancers and Lupus.

AstraZeneca to buy Chinese drug firm in billion dollar deal

Pharmaceutical giants AstraZeneca plc (NASDAQ:AZN) and Bristol-Myers Squibb Co  (NYSE:BMY) announced new acquisitions today.

Acquisitions Push 2 Pharma Stocks in Opposite Directions

Gracell Biotechnologies acquisition marks China's growing importance to the Anglo-Swedish drugmaker

AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn

Gracell Biotechnologies

Dec 26 (Reuters) - AstraZeneca (AZN.L) said on Tuesday it will buy Gracell Biotechnologies (GRCL.O) for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world's second-largest pharmaceuticals market.

AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal

AstraZeneca's acquisition of Gracell is expected to close in the first quarter of 2024.

AstraZeneca to Acquire China's Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

BioMarin Pharmaceutical

Blueprint Medicines

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Eli Lilly

Novartis

Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.

These 3 Big Pharma Stocks Are Making Big Plays With AI

Ionis Pharma

Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.

Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment

The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.

US FDA approves Ionis-AstraZeneca's nerve disease drug

Novo Nordisk

The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry

Lloyds Banking Group

Rolls-Royce Holdings PLC

For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That, at least, is the conclusion of Liberum, the boutique investment bank, in assessing the tactics to deploy over the next 12 months.

Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?

Compugen

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, AstraZeneca's anti-PD-L1 therapy, in two types of breast cancer. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo.

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

News for AstraZeneca Stock (AZN)